Inflammatory conditions

As a company that is committed to improving access to healthcare, we are constantly looking to bring new treatments to market that meet this goal and will greatly enhance the lives of patients at an affordable cost to providers. We are therefore especially proud to launch Europe’s first biosimilar monoclonal antibody for the treatment of inflammatory conditions including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Biosimilars are so-called because they are developed to be highly similar to already marketed biologics, known as reference products.1 They have the potential to improve the lives of people around the world by expanding treatment options to people with debilitating inflammatory conditions as they are typically made available at a lower cost than the reference product, after the patents and Supplementary Protection Certificates protecting that product have expired.2 Prior to approval by the European Medicines Agency, biosimilars undergo rigorous comparability testing for quality, safety and efficacy to ensure they are comparable to the reference product3

The product range includes:

  Remsima® (infliximab) is the first authorised biosimilar monoclonal antibody by the EMA, a new-generation value-based biologic

Lodotra® (modified-release prednisone) - an innovative programmed-release formulation for the treatment of rheumatoid arthritis in adults, particularly those who suffer from accompanied morning stiffness.


1. Biological and Biosimilar Medicines Fact Sheet 2: An Information and Advocacy Toolkit for Patients' Organizations, IAPO Last accessed 7.10.14

2. What you need to know about biosimilar medicinal products. Consensus document, European Commission 2013 Last access 13.10.14

3. Quick Guide on Biological and Biosimilar Medicines. IAPO November 2013 Last accessed 7.10.14

Key facts